胰岛炎
点头老鼠
间充质干细胞
胃泌素
免疫系统
医学
内科学
点头
内分泌学
干细胞
离体
小岛
1型糖尿病
胰岛素
癌症研究
免疫学
体内
生物
糖尿病
分泌物
病理
细胞生物学
生物技术
作者
Marie‐Claude Gaudreau,Radhika Gudi,Gongbo Li,Benjamin M. Johnson,Chenthamarakshan Vasu
出处
期刊:Autoimmunity
[Informa]
日期:2021-12-09
卷期号:55 (2): 95-108
被引量:10
标识
DOI:10.1080/08916934.2021.2012165
摘要
Progressive destruction of pancreatic islet β-cells by immune cells is a primary feature of type 1 diabetes (T1D) and therapies that can restore the functional β-cell mass are needed to alleviate disease progression. Here, we report the use of mesenchymal stromal/stem cells (MSCs) for the production and delivery of Gastrin, a peptide hormone that is produced by intestinal cells and foetal islets and can increase β-Cell mass, to promote protection from T1D. A single injection of syngeneic MSCs that were engineered to express Gastrin (Gastrin-MSCs) caused a significant delay in hyperglycaemia in non-obese diabetic (NOD) mice compared to engineered control-MSCs. Similar treatment of early-hyperglycaemic mice caused the restoration of euglycemia for a considerable duration, and these therapeutic effects were associated with the protection of, and/or higher frequencies of, insulin-producing islets and less severe insulitis. While the overall immune cell phenotype was not affected profoundly upon treatment using Gastrin-MSCs or upon in vitro culture, pancreatic lymph node cells from Gastrin-MSC treated mice, upon ex vivo challenge with self-antigen, showed a Th2 and Th17 bias, and diminished the diabetogenic property in NOD-Rag1 deficient mice suggesting a disease protective immune modulation under Gastrin-MSC treatment associated protection from hyperglycaemia. Overall, this study shows the potential of production and delivery of Gastrin in vivo, by MSCs, in protecting insulin-producing β-cells and ameliorating the disease progression in T1D.
科研通智能强力驱动
Strongly Powered by AbleSci AI